InVitria launches xeno-free formulation service within $5.2bn media market

By InVitria launches xeno-free service within $5.2bn media market

- Last updated on GMT

GettyImages/JVisentin
GettyImages/JVisentin

Related tags: Cell culture media, Cell culture, Cell

Xeno-free media will continue to increase its share of the estimated 30m litre mammalian cell culture market says InVitria, which has launched a new formulation service.

The subsidiary of Ventria Bioscience launched the cell culture media formulation service at the BIO-Europe conference in Berlin, Germany this week, based on its portfolio of supplements made in its completely animal-free system.

“This new service is an extension of the knowledge we have gained in working with our current product line,”​ Randy Alfano, VP of InVitria Product Development, told Biopharma-Reporter. “We have extensive experience in the incorporation of our blood free components into complete media formulations and have already demonstrated success in the market in converting manufacturing processes to be blood free.”

The firm is offering access to its animal component free cell culture media formulations to preclinical and early-phase clinical firms developing stem cell, immunotherapies, and novel vaccines.

“Every media formulation we develop is completely void of any animal or human-serum derived components, a type of cell culture media that we refer to as ‘Blood Free.’ Further, these media are void of any undefined substances such as plant hydrolysates.”

Rise of animal-free media

InVitria estimates the total mammalian cell culture market to around 30 million liters annually, which is worth around $5.2bn. And according to Alfano xeno-free serums are taking an increasingly larger percentage of that market.

“We believe that recombinant protein expression technology and knowledge in media development has essentially progressed to the point that inclusion of serum or serum-derived proteins is an obsolete approach that has an unacceptable risk in terms of patient safety.”

InVitria is one of a number of firms offering xeno-free options to cell therapy and biopharma firms.

Over the past couple of years, Corning​, Irvine Scientific​, Evercyte​ and Worthing​ have all upped their presence in the space.

Related news

Show more

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Related suppliers

Follow us

Products

View more

Webinars